KRAS and non-small cell lung carcinoma: Conversely, Lin et al. retrospectively evaluated 62 ROS1-rearranged NSCLC (confirmed by FISH, PCR or sequencing or both techniques), reporting only two cases with concomitant KRAS mutation and a higher proportion of concurrent non-druggable mutations, such as TP53 (25.2%), CTNNB1 (7%) and CDKN2A/B loss (13.6%), whose role and therapeutic relevance must be clarified [100].